8-K: Elicio Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Updates

Elicio Therapeutics announced its Q1 2025 financial results, highlighting progress towards the Phase 2 AMPLIFY-7P interim analysis and alignment with the FDA on a Phase 3 study design for ELI-002.

Summary

• Elicio Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company is focused on the upcoming Phase 2 AMPLIFY-7P event-driven interim analysis, expected in Q3 2025.
• Elicio has aligned with the FDA on key design elements for a planned Phase 3 study of ELI-002 in post-resection mKRAS PDAC.
• The company's current cash position is expected to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis into Q4 2025.
• R&D expenses for Q1 2025 were $7.8 million, compared to $7.6 million for Q1 2024.
• G&A expenses for Q1 2025 were $3.0 million, compared to $2.7 million for Q1 2024.
• Net loss for Q1 2025 was $11.2 million, compared to $11.8 million for Q1 2024.
• Net loss per share for Q1 2025 was $0.87 compared to $1.15 for Q1 2024.
• Cash and cash equivalents as of March 31, 2025, were $18.4 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to progress in clinical trials, FDA alignment, and sufficient cash runway, but tempered by ongoing losses and the inherent risks of drug development.

Positives

• Elicio has aligned with the FDA on key design elements for a planned Phase 3 study of ELI-002, de-risking the development pathway.
• The company's cash runway extends into Q4 2025, providing financial stability through the anticipated Phase 2 interim analysis.
• Elicio strengthened its cash position with a $10.0 million registered direct offering.
• The company is making progress toward the Phase 2 AMPLIFY-7P event-driven interim analysis, expected in Q3 2025.

Negatives

• The company reported a net loss of $11.2 million for Q1 2025.
• The company's cash and cash equivalents as of March 31, 2025, were $18.4 million.

Risks

• The success of the ELI-002 program is dependent on the outcome of the Phase 2 AMPLIFY-7P interim analysis.
• The company's ability to continue as a going concern is dependent on its ability to obtain additional funding.
• Clinical trials are subject to delays and unexpected results.
• The company's product candidates may not receive regulatory approval.

Future Outlook

Elicio anticipates an interim analysis of the Phase 2 AMPLIFY-7P clinical trial in Q3 2025 and potential finalization of the Phase 3 trial protocol for ELI-002 in H2 2025. The company expects its current cash to support operations into Q4 2025.

Management Comments

• Robert Connelly, Chief Executive Officer of Elicio, stated that the company made continued progress toward its upcoming Phase 2 AMPLIFY-7P event-driven interim analysis.
• Management believes ELI-002 represents a potentially transformative approach in the treatment of mKRAS-driven tumors.
• Management believes the upcoming results could demonstrate ELI-002's impact not only in PDAC but also provide momentum for broader application of the technology across additional indications.

Industry Context

Elicio is developing off-the-shelf cancer vaccines, which offer potential advantages over personalized vaccines in terms of cost, manufacturing scalability, and rapid availability. The company's focus on mKRAS-driven tumors addresses a significant unmet need in cancer treatment.

Comparison to Industry Standards

• Elicio's approach to targeting the lymph nodes with its AMP platform is similar to strategies employed by companies like BioNTech and Moderna in their mRNA vaccine development.
• The 5-year survival rate of 13% for PDAC highlights the significant unmet need in this area, making Elicio's ELI-002 a potentially valuable asset if it proves effective.
• The company's focus on off-the-shelf vaccines aligns with the industry trend towards scalable and cost-effective cancer immunotherapies, contrasting with personalized approaches like those pursued by companies such as Gritstone Bio.

Management Changes

Stakeholder Impact

• Positive results from the AMPLIFY-7P trial could benefit patients with mKRAS-positive pancreatic cancer.
• Shareholders may see increased value if ELI-002 progresses successfully through clinical trials.
• Employees are likely to be impacted by the company's progress and financial performance.

Next Steps

• Elicio will conduct the DFS event-driven interim analysis of the Phase 2 AMPLIFY-7P clinical trial in Q3 2025.
• The company may finalize the pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in H2 2025.
• Elicio plans to expand ELI-002 to other indications including mKRAS positive lung cancer and other mKRAS positive cancers.

Key Dates

Keywords

Elicio Therapeutics, ELI-002, AMPLIFY-7P, mKRAS, PDAC, Immunotherapy, Clinical Trial, Phase 2, Phase 3, FDA, Financial Results, Cash Runway